生物制药公司Sarepta Therapeutics（SRPT）夜盘大跌5.10%，引发投资者关注。这一跌势主要源于公司近期遭遇的一系列负面消息。
据报道，Sarepta Therapeutics计划裁员36%，约500人，原因是其基因疗法Elevidys遭遇重大挫折。该公司披露，使用Elevidys治疗的两名患者不幸身亡，这一事件严重打击了投资者对该疗法的信心。更加雪上加霜的是，美国食品和药物管理局（FDA）决定对Elevidys增加黑框警告，提示其存在严重的肝脏风险。
值得注意的是，Elevidys是FDA批准的唯一一种用于治疗四岁及以上杜氏肌营养不良症患者的基因疗法。这次事件无疑会对Sarepta的核心业务造成重大影响。与此同时，公司宣布任命Ryan Wong为新任首席财务官，但这一人事变动似乎未能提振投资者信心。分析人士指出，Sarepta面临的挑战可能会持续一段时间，投资者需密切关注公司后续的应对措施及Elevidys的进一步发展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.